Document Detail

Challenging the superiority of amiodarone for rate control in Wolff-Parkinson-White and atrial fibrillation.
MedLine Citation:
PMID:  20437113     Owner:  NLM     Status:  MEDLINE    
The objective of this review is to explore and challenge the superiority of amiodarone for rate control in Wolff-Parkinson-White syndrome and concomitant atrial fibrillation (WPW-AF). The current recommendation for pharmacological treatment of this condition is amiodarone. A review of the past 25 years of literature finds several studies that identify a small risk of ventricular fibrillation secondary to amiodarone administration for rate control in WPW-AF. Additionally, the literature supports the safe and effective use of procainamide for rate control in WPW-AF. This review concludes that amiodarone is not superior to procainamide in rate control for WPW-AF, and may be dangerous.
Sharis M Simonian; Shahram Lotfipour; Christopher Wall; Mark I Langdorf
Related Documents :
16823233 - Epidemiological and etiological study of oral submucous fibrosis among gutkha chewers o...
17341883 - Prognos in the diagnosis of amalgam hypersensitivity a diagnostic case-control study.
6996013 - Immediate repair of upper lip defect with a cross-lip flap.
Publication Detail:
Type:  Case Reports; Journal Article; Review     Date:  2010-05-01
Journal Detail:
Title:  Internal and emergency medicine     Volume:  5     ISSN:  1970-9366     ISO Abbreviation:  Intern Emerg Med     Publication Date:  2010 Oct 
Date Detail:
Created Date:  2010-09-20     Completed Date:  2011-01-24     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101263418     Medline TA:  Intern Emerg Med     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  421-6     Citation Subset:  IM    
Department of Emergency Medicine, University of California-Irvine School of Medicine, 101 The City Drive, Orange, CA 92868, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Amiodarone / therapeutic use*
Anti-Arrhythmia Agents / therapeutic use*
Atrial Fibrillation / diagnosis,  drug therapy*,  etiology
Emergency Service, Hospital
Procainamide / therapeutic use*
Tachycardia / drug therapy*,  etiology
Wolff-Parkinson-White Syndrome / complications,  drug therapy*
Reg. No./Substance:
0/Anti-Arrhythmia Agents; 1951-25-3/Amiodarone; 51-06-9/Procainamide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Rapid urease test for H. pylori diagnosis: pros and cons.
Next Document:  Selecting Patients for Epilepsy Surgery.